CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be

- a) a guide for reporting for authors of RCTs,
- b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (nonpharmacologic treatment) items. Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED). Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS

ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption): Eysenbach G, CONSORT-EHEALTH Group CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions J Med Internet Res 2011;13(4):e126 URL: <u>http://www.jmir.org/2011/4/e126/</u> doi: 10.2196/jmir.1923 PMID: 22209829

* Required

Your name *

First Last

Mohan Madisetti

Primary Affiliation (short), City, Country *

University of Toronto, Toronto, Canada

Medical University of South Carolina

Your e-mail address *

abc@gmail.com

madisett@musc.edu

Title of your manuscript *

Provide the (draft) title of your manuscript.

A Lower Leg Physical Activity Intervention for Individuals With Chronic Venous Leg Ulcers: Randomized Controlled Trial

Name of your App/Software/Intervention *

If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

FOOTFIT

Evaluated Version (if any)

e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

Your answer

Language(s) *

What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

English

URL of your Intervention Website or App

e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

Your answer

URL of an image/screenshot (optional)

Your answer

Accessibility *

Can an enduser access the intervention presently?

-) access is free and open
- access only for special usergroups, not open

access is open to everyone, but requires payment/subscription/in-app purchases

- app/intervention no longer accessible
- Other:

Primary Medical Indication/Disease/Condition *

e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

Individuals with venous leg ulcers.

Primary Outcomes measured in trial *

comma-separated list of primary outcomes reported in the trial

Feasibility of the FOOTFIT exercise program


Secondary/other outcomes

Are there any other outcomes the intervention is expected to affect?

Your answer

Recommended "Dose" *

What do the instructions for users say on how often the app should be used?



Other:

Approx. Percentage of Users (starters) still using the app as recommended after 3 months *

- 0-10%
- 11-20%
- 21-30%
-) 31-40%
- 41-50%
- 51-60%
- 61-70%
- 71%-80%

0 8	1-90%
-----	-------

91-100%

Other:

Ove	erall, was the app/intervention effective? *
0	yes: all primary outcomes were significantly better in intervention group vs control
0	partly: SOME primary outcomes were significantly better in intervention group vs control
0	no statistically significant difference between control and intervention
0	potentially harmful: control was significantly better than intervention in one or more outcomes
$oldsymbol{O}$	inconclusive: more research is needed
0	Other:
	cle Preparation Status/Stage * hich stage in your article preparation are you currently (at the time you fill in this form)
Ο	not submitted yet - in early draft status

- not submitted yet in late draft status, just before submission
- submitted to a journal but not reviewed yet
- submitted to a journal and after receiving initial reviewer comments
- submitted to a journal and accepted, but not published yet
 -) published
 - Other:

Journal *

If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- not submitted yet / unclear where I will submit this
- Journal of Medical Internet Research (JMIR)
- JMIR mHealth and UHealth
- JMIR Serious Games
- JMIR Mental Health
- JMIR Public Health
- JMIR Formative Research
- Other JMIR sister journal
- Other:

Is this a full powered effectiveness trial or a pilot/feasibility trial? *

Pilot/feasibility

) Fully powered

Manuscript tracking number *

If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

) no ms number (yet) / not (yet) submitted to / published in JMIR

Other: 15015


TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? *
I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")
• yes
O Other:

1a-i) Identify the mode of delivery in the title


Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.



Does your paper address subitem 1a-i?*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This item is addressed in the Abstract: "The primary objective was to establish the feasibility of a mobile health (mHealth) smartphone physical activity exercise application (app) for individuals with VLUs to improve lower leg function."




Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This item is addressed in the Methods: "Participants were randomized 1:1 to receive evidence-based, phased, non-exertive physical conditioning activities for lower leg function (FOOTFIT) or FOOTFIT+ with an added patient-provider communication feature."

1a-iii) Primary condition or target group in the title

Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial



Does your paper address subitem 1a-iii? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


Yes. "A Lower Leg Physical Activity Intervention for Individuals With Chronic Venous Leg Ulcers: Randomized Controlled Trial"

1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



Does your paper address subitem 1b-i?*

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Participants were randomized 1:1 to receive evidence-based, phased, non-exertive physical conditioning activities for lower leg function (FOOTFIT) or FOOTFIT+ with an added patient-provider communication feature. The mHealth CALF smartphone app also provided automated educational/motivational messages and user reports. Foot movement on the VLU-affected leg was tracked by a Bluetooth enabled tri-axial accelerometer. The study was guided by the RE-AIM framework to assess feasibility of reach, adherence, acceptability, implementation and maintenance."

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)




Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Participants were randomized 1:1 to receive evidence-based, phased, non-exertive physical conditioning activities for lower leg function (FOOTFIT) or FOOTFIT+ with an added patient-provider communication feature. The mHealth CALF smartphone app also provided automated educational/motivational messages and user reports. Foot movement on the VLU-affected leg was tracked by a Bluetooth enabled tri-axial accelerometer. The study was guided by the RE-AIM framework to assess feasibility of reach, adherence, acceptability, implementation and maintenance."

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "In a 6-week feasibility study, adults with VLUs were recruited from two wound centers in South Carolina, USA and enrolled if they were 18 years of age or older with impaired functional mobility, and ankle brachial index (ABI) between 0.8-1.3."

1b-iv) RESULTS section in abstract must contain use data								
Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)								
1	2	3	4	5				
0	0	0	۲	0	essential			
	ed/assess time, nun bstract wł onsider a	ed/assessed in each time, number of log bstract what the ma onsider adding it)	ed/assessed in each group, the time, number of logins etc.), i bstract what the main paper is onsider adding it)	ed/assessed in each group, the use/upta time, number of logins etc.), in addition bstract what the main paper is reporting	ed/assessed in each group, the use/uptake of the i time, number of logins etc.), in addition to primary bstract what the main paper is reporting. If this inf onsider adding it)			

Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Twenty-four patients were recruited and enrolled in the study."

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	٢	essential

Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


Yes. "Findings suggest that despite initial interest in using the app, several components of the program as originally designed had limited acceptability and feasibility. Future refinements should include the use of more modern technology including smaller wearable accelerometers, Smartphones or tablets with larger screens, an app designed with larger graphics, automated reporting for providers, and more engaging user features."

INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)



Does your paper address subitem 2a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Individuals with venous leg ulcers (VLUs) suffer disproportionately with multiple chronic conditions and demonstrate high levels of inactivity [1,2]. Many are physically deconditioned and minimally ambulatory, able to only take a few steps at a time, are slow walkers, and have poor standing balance [3]. Obesity, older age, and leg pain are common characteristics that negatively impact functional abilities [4]. Reduced range of motion of the ankle and decreased calf muscle contractility with increased muscle deoxygenation are known physical impairments that also contribute to worsening condition of the lower legs, and substantially further restrict mobility [5]. These processes also contribute to poor wound healing outcomes.

"While numerous study findings suggest physical activity is important for improving outcomes in patients with ulcers, there are inconsistent findings about which types of programs are feasible for functionally impaired individuals with multiple chronic conditions. For those with leg wounds from venous or arterial diseases, enhanced healing and physical and functional abilities are key outcomes of physical activity programs."

"To address this need, our team developed and tested a foot-based BluetoothTM-enabled acceleration tracking device and smartphone application system (BEAT) and demonstrated its reliability and validity in laboratory experiments using a standard rotary-shaker test with 4 accelerometers (coefficient of variation was found to be 0.7%) and tested its feasibility in minimally ambulatory patients with venous disease and de-conditioned legs [18]. BEAT detected even very minimal toe movements, which were captured by a smartphone app developed for mobile phones that received information from the accelerometer."

2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	٢	essential

Does your paper address subitem 2a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "We previously conducted two small pilot studies of physical activity that informed the development of our study's intervention methods. The first was a home-based online physical activity intervention developed by our team of physical therapists and exercise specialists that included resistance bands, non-exertive foot movements, and a foot peddler (similar to peddling a bicycle), delivered by a coach (nursing student with degree in exercise science) through online face-to-face internet sessions [11]. Five participants with venous disease and a history of VLUs participated in determining the feasibility of engaging in three daily doses of non-exertive conditioning physical activities for lower leg function (CALF) for one week. We observed a very high level of patient satisfaction with working with the coach and using the equipment to engage in a variety of lower leg exercises. We found the study procedures including engagement using the Skype® interface were feasible. Enhancements were made to CALF, one of which was the addition of a behavioral, motivational interviewing (MI) component, in our second six-week study of 21 minimally ambulatory patients randomized to the CALF intervention or an exercise handout [12]. Certified wound care nurses were trained on MI communication techniques to interact with patients about engaging in exercises who were receiving wound care in a specialty clinic. We included only the non-exertive foot movements (did not use the peddler or resistance bands in this version of CALF) due to patients having ulcers and their lower legs being wrapped with multi-layer compression that restricted ankle movement. The CALF intervention was found to be feasible and acceptable by both patients and the nurses who delivered it. However, having a coach and using providers who require special training is costly and not always available outside the clinic setting as not all patients receive care in specialized wound clinics. Further, many patients do not have access to physical therapy specialists or readily available transportation to attend exercise programs in the community, and due to having wounds and or functional impairments, many find it difficult to engage in physical activity."

2b) In INTRODUCTION: Specific objectives or hypotheses

Does your paper address CONSORT subitem 2b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. ". The primary aim of the study was to explore the feasibility of an exercise program comprised of an accelerometer-app combination, initiated during wound clinic visits, and performed by patients with VLUs in their homes."

METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The main outcome of this study was feasibility; sample size was determined based on pragmatic reasons. The aim was to recruit 24 participants who were randomized to FOOTFIT or FOOTFIT+ on a 1:1 ratio after baseline data collection."

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study									
Not applicable. The methods did not change.									
3b-i) Bug fixes, Downtimes, C Bug fixes, Downtimes, Content Chang changes to methods therefore also in during the trial (e.g., major bug fixes o "unexpected events" that may have in failures/downtimes, etc. [2].	ges: eheal ncludes im or change	th systems portant cl s in the fu	s are often nanges ma nctionality	ade on the v or conter	interventio nt) (5-iii) ar	on or comparator nd other			
	1	2	3	4	5				
subitem not at all important	۲	0	0	0	0	essential			

Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable. However system weaknesses are discussed in the Limitation section.

4a) Eligibility criteria for participants

Does your paper address CONSORT subitem 4a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Inclusion criteria were being age 18 years and above, having a VLU, ankle brachial index of 0.80 to 1.3 to rule out arterial insufficiency, receiving at least weekly wound care anticipated to last for at least six weeks from start of study, being able to don the slipper onto which BEAT was affixed or having assistance from other, and being capable of using a smartphone (individual observed using his or her phone after enrollment at baseline). Individuals were excluded if they had a co-morbid condition such as stroke or severe arthritis that limited ankle function, an ulcer from other causes such as arterial, surgical or traumatic, cognitive impairment determined by less than 3 recalled words and abnormal clock drawing on the MiniCog test [20] administered at baseline, or no 3G service available where the participant resided. "

4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	٢	essential

Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. This is described in the eligibility inclusion / exclusion criteria. "being capable of using a smartphone (individual observed using his or her phone after enrollment at baseline).... or no 3G service available where the participant resided. "

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely webbased trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

	1	2	3	4	5	
subitem not at all important	0	0	۲	0	0	essential

Does your paper address subitem 4a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Participants were recruited through direct referral from two participating wound clinics in the Southeastern region of the U.S.A. "

4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential

Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Patients were instructed to perform each level for 2 weeks, 3 times per day for a minimum of 15 seconds each per activity, advancing in frequency and intensity. The BEAT was worn on the foot, affixed to a special slipper, during CALF to capture frequency and intensity of movements. The app on the smartphone reminded individuals to perform the exercises at pre-set times each day, per patient preference, and sent patients supportive feedback after each daily session. There were also 12 short video clips of how to perform each movement and 16 short audiorecorded, evidenced-based information sessions about managing venous disease, the latest development in ulcer treatment, and other topics of interest expressed by individuals in our previous studies such as why compression is needed, what medications help healing, and how best to elevate the legs to reduce edema. FOOTFIT+ was enhanced with an added phone, email or text messaging connectivity feature to the wound care providers. The providers were instructed by the study principal investigator on theory-based patient-provider "talk" communication [21]. The providers were to make weekly contact with the participant via phone, email or text, per participant preference, and provide a brief report of progress towards goals. "

4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Data were collected pre-intervention at the baseline visit and at post-intervention during the last visit week. "

4b-i) Report if outcomes were (self-)assessed through online questionnaires Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.									
	1	2	3	4	5				
subitem not at all important	0	0	۲	0	0	essential			
,	Does your paper address subitem 4b-i? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to								
indicate direct quotes from your man information not in the ms, or briefly e	uscript), c	or elaborat	e on this i	tem by pro	oviding add	ditional			
Not applicable.									
4b-ii) Report how institution	al affilia [.]	tions are	e display	/ed					
Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention.(Not a required item – describe only if this may bias results)									
	1	2	3	4	5				
subitem not at all important	0	۲	0	0	0	essential			

Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable.

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

5-i) Mention names, credential, affiliations of the developers, sponsors, and

owners

Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).

	1	2	3	4	5	
subitem not at all important	0	0	۲	0	0	essential

Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. This is a NIH/NINR sponsored project.

5-ii) Describe the history/development process Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with								
interpreting results.				•		·		
	1	2	3	4	5			
subitem not at all important	0	0	0	0	٢	essential		

Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. Pilot work is described in the Introduction section.

5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).


	1	2	3	4	5	
subitem not at all important	0	۲	0	0	0	essential

Does your paper address sub	oitem 5-	-iii?				
Copy and paste relevant sections from indicate direct quotes from your man information not in the ms, or briefly e	uscript), o	or elaborat	e on this i	tem by pro	oviding add	ditional
Not applicable.						
5-iv) Quality assurance meth	nods					
Provide information on quality assura provided [1], if applicable.	ance meth	ods to ens	sure accur	acy and qı	uality of in	formation
	1	2	3	4	5	
subitem not at all important	0	0	0	0		essential

Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "If the prescribed activity was not being performed for two consecutive days by the participant, the providers were notified via text, and reminded to contact the patient to verify the accelerometer was functioning and discuss any problems."



Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Materials are available upon request to the Corresponding Author.

5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, <u>webcitation.org</u>, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

	1	2	3	4	5	
subitem not at all important	۲	0	0	0	0	essential

Copy and paste relevant sections fro indicate direct quotes from your man information not in the ms, or briefly e	iuscript), c	or elaborat	e on this i	tem by pro	oviding add	litional
Not applicable to this pilot trial.						
5-vii) Access Access: Describe how participants a (or were paid) or not, whether they ha participants obtained "access to the editors/reviewers/readers, consider t reviewers/readers to explore the app	ad to be a platform a to provide	member o and Interne a "backdo	f specific et" [1]. To e or" login a	group. If k ensure acc iccount or	nown, des cess for demo mo	cribe how de for
	1	2	3	4	5	

Does your paper address subitem 5-vii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The app was designed for iOS 8 or later, developed on Heroku cloud platform and beta tested through Apple TestFlight. Every three months the app's beta testing period expired and a new build of the app had to be uploaded by the developers to TestFlight for actively using the app."

5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].



Does your paper address subitem 5-viii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The CALF program for this study consisted of 3 levels of phased, non-exertive movements for the lower legs, beginning with the most minimal Level 1 intensity with foot on the floor progressing to Level 2 intensity with heal on the floor and forefoot elevated, to maximal Level 3 intensity with foot off the floor. Patients were instructed to perform each level for 2 weeks, 3 times per day for a minimum of 15 seconds each per activity, advancing in frequency and intensity. The BEAT was worn on the foot, affixed to a special slipper, during CALF to capture frequency and intensity of movements. The app on the smartphone reminded individuals to perform the exercises at pre-set times each day, per patient preference, and sent patients supportive feedback after each daily session. There were also 12 short video clips of how to perform each movement and 16 short audiorecorded, evidenced-based information sessions about managing venous disease, the latest development in ulcer treatment, and other topics of interest expressed by individuals in our previous studies such as why compression is needed, what medications help healing, and how best to elevate the legs to reduce edema.

FOOTFIT+ was enhanced with an added phone, email or text messaging connectivity feature to the wound care providers."

5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential

Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Patients were instructed to perform each level for 2 weeks, 3 times per day for a minimum of 15 seconds each per activity, advancing in frequency and intensity. "

"The providers were informed that participants could contact them during normal business hours using any mode (phone, email, text, voicemail) but the communication was to be related to the physical activity program only, such as pain during CALF and progress towards meeting goals."

5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).




Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The providers were to make weekly contact with the participant via phone, email or text, per participant preference, and provide a brief report of progress towards goals."

5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).



Does your paper address subitem 5-xi?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "If the prescribed activity was not being performed for two consecutive days by the participant, the providers were notified via text, and reminded to contact the patient to verify the accelerometer was functioning and discuss any problems."

5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	٢	essential

Does your paper address subitem 5-xii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The providers were informed that participants could contact them during normal business hours using any mode (phone, email, text, voicemail) but the communication was to be related to the physical activity program only, such as pain during CALF and progress towards meeting goals."

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

Does your paper address CONSORT subitem 6a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Intervention feasibility assessment was guided by the RE-AIM framework for reach, effectiveness, adoption, adherence, acceptability, implementation, and maintenance [22,23). Reach was measured by continuous progress monitoring of sample representativeness, how patients learned about the study, types of recruitment activities and rates, meeting of recruitment goals (1 out of 5 patients approached and eligible would be consented), number of eligible patients approached, consented and oriented to the study. These data were captured on tracking forms, and quality checks were performed weekly and discussed at weekly team meetings. Data captured by the accelerometer BEAT was reported as the percentage of participants adherent to exercise duration defined as performing foot exercises at or above the recommended duration of \geq 15 seconds for each exercise (three exercises per session, three times per day) or not always adherent (moved foot < 15 seconds per exercise per session). Adherence to frequency was reported as the percentage of days the participants completed each CALF intensity level (3 levels performed 3 times per day [=9 levels], each performed over 2 weeks); 9 levels performed \geq 85% of the days throughout the study period was considered adherent to frequency. Participants were instructed to perform the exercises three times daily, increase the duration of time each subsequent day, and review additional information on the app as needed. The number and reasons for dropouts were also recorded. Adoption focused on patient-provider communication and was measured by review of 10% of calls/emails/texts between participant and provider via content analysis of communication interactions (i.e., information sought, reassurance given, call was of a social nature). We also assessed whether the provider was checking progress reports and graphs, and how the participant rated communication; this information was recorded on tracking forms and assessed at weekly team meetings. The goal for the provider was to use the "talk" model 90% of the time, and that 90% of participants would report high satisfaction. Acceptability was defined as endorsement and measured by the number and types of problems encountered such as difficulty using accelerometer and smartphone app and satisfaction with the communication system. Implementation procedures included participant and wound care provider recommendations used to refine CALF or BEAT, and the number and types of refinements made. Maintenance was defined as the number of patients who would continue the intervention, and the provider perception of impact and potential for future applications. Safety was evaluated by recording any adverse effects or safety issues such as cramping or new leg pain that occurred during the study period. Treatment fidelity was monitored weekly and assessed retrospectively from data obtained from BEAT in terms of the number of daily exercises completed per participant over the length of the study."

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were									
designed/deployed									
If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].									
	1	2	3	4	5				
subitem not at all important	۲	0	0	0	0	essential			

Does your paper address subitem 6a-i?

Copy and paste relevant sections from manuscript text

No online surveys were administered.

6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored

Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	٢	essential


Does your paper address subitem 6a-ii?

Copy and paste relevant sections from manuscript text

Yes. "Data captured by the accelerometer BEAT was reported as the percentage of participants adherent to exercise duration defined as performing foot exercises at or above the recommended duration of \geq 15 seconds for each exercise (three exercises per session, three times per day) or not always adherent (moved foot < 15 seconds per exercise per session). Adherence to frequency was reported as the percentage of days the participants completed each CALF intensity level (3 levels performed 3 times per day [=9 levels], each performed over 2 weeks); 9 levels performed \geq 85% of the days throughout the study period was considered adherent to frequency."

6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained

Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).



Does your paper address subitem 6a-iii? Copy and paste relevant sections from manuscript text

This was not an study aim.

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CC	ONSORT	l subiter	n 6b? *						
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional									
information not in the ms, or briefly e					•				
Not applicable. No changes were	e made.								
7a) How sample size was de	termine	ed							
NPT: When applicable, details of whe addressed	ther and h	now the clu	ustering b	y care prov	vides or ce	nters was			
7a-i) Describe whether and h	now exp	pected a	ttrition	was take	en into a	ccount when			
calculating the sample size									
Describe whether and how expected	attrition w	/as taken i	nto accou	nt when ca	alculating 1	the sample size.			
	1	2	3	4	5				
subitem not at all important	0	0		0	0	essential			
Subtom not at an important	-	-	-	-	*	coontin			

Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No. This is more fully explained in the Statistical Analysis Section: "Due to the small sample size normally distributed data were not assumed. No hypothesis testing was carried out and therefore no p-values are provided in concordance with recommendations in the CONSORT 2010 statement for randomized pilot and feasibility trials [24]. Similarly, no effect sizes (e.g. Cohen's d) were provided due to large imprecision with small sample sizes [25]. Instead, 95% confidence intervals (CIs) for differences in medians between groups were obtained using quantile regression while differences in proportions of categorical feasibility outcomes with their corresponding 95% CIs were obtained using Newcombe risk difference method, to describe estimates of the magnitude of the clinical effects. "

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No, There were no stopping rules for this feasibility study.

8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "A computer-generated random number schema was developed by the statistician who had no contact with the participants."

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "24 participants who were randomized to FOOTFIT or FOOTFIT+ on a 1:1 ratio.."

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Group allocation was concealed in a database and revealed to the data collector after baseline data were collected and entered to minimize selection and measurement bias."

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "A computer-generated random number schema was developed by the statistician who had no contact with the participants"

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how NPT: Whether or not administering co-interventions were blinded to group assignment

	1	2	3	4	5	
subitem not at all important	0	۲	0	0	0	essential
Does your paper address su	bitem 11	la-i? *				
indicate direct quotes from your man	uscript), d	or elaborat	e on this i	tem by pro	oviding add	ditional
indicate direct quotes from your man information not in the ms, or briefly e	uscript), d	or elaborat	e on this i	tem by pro	oviding add	ditional
indicate direct quotes from your man information not in the ms, or briefly e No. This was a feasibility trial.	uscript), o	or elaborat y the item	e on this i is not app	tem by pro licable/re	oviding add	ditional your study
indicate direct quotes from your man information not in the ms, or briefly e No. This was a feasibility trial. 11a-ii) Discuss e.g., whether "intervention of interest" and	particip	ants kne	e on this i is not app ew whic s the "co	h intervo	ention w	ditional your study yas the
indicate direct quotes from your man information not in the ms, or briefly e No. This was a feasibility trial. 11a-ii) Discuss e.g., whether "intervention of interest" and Informed consent procedures (4a-ii) participants knew which intervention	particip d which	ants kne one was	e on this i is not app ew whic s the "co nd certain	h interve	ention w or" ons - discu	ditional your study vas the ss e.g., whether
Copy and paste relevant sections fro indicate direct quotes from your man information not in the ms, or briefly e No. This was a feasibility trial. 11a-ii) Discuss e.g., whether "intervention of interest" and Informed consent procedures (4a-ii) participants knew which intervention "comparator".	particip d which	ants kne one was biases an	e on this i is not app ew whic s the "co nd certain	tem by pro licable/re h interve omparat expectations est" and w	ention w or" ons - discu hich one w	ditional your study vas the ss e.g., whether

Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No. However, group allocations are discussed in the Informed Consent document.

11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "FOOTFIT+ was enhanced with an added phone, email or text messaging connectivity feature to the wound care providers."

12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

Does your paper address CONSORT subitem 12a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "... no effect sizes (e.g. Cohen's d) were provided due to large imprecision with small sample sizes [25]. Instead, 95% confidence intervals (CIs) for differences in medians between groups were obtained using quantile regression while differences in proportions of categorical feasibility outcomes with their corresponding 95% CIs were obtained using Newcombe risk difference method, to describe estimates of the magnitude of the clinical effects."

12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

	1	2	3	4	5	
subitem not at all important	0	٢	0	0	0	essential

Does your paper address subitem 12a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No, However, this study was conducted under the intention to treat principal, with no imputation of missing data.

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does your paper address C	CONSORT subitem 12b? *
---------------------------	------------------------

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable to this feasibility trial.

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

X26-i) Comment on ethics co	ommitte	e appro	oval			
	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential


Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The trial complied with the Consolidated Standards of Research Trials (CONSORT)-EHEALTH guidelines [19], was approved by the Medical University of South Carolina Institutional Review Board (#00043451), and registered with ClinicalTrials.gov NCT02632695 on December 17, 2015. "

x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.



Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Written informed consent was required to participate and obtained prior to enrollment in the study in which two visits occurred, one at baseline and one at 6 weeks." Consent was gained in-person.

X26-iii) Safety and security procedures. Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline) 1 2 3 4 5 subitem not at all important O O O O essential

Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The providers were informed that participants could contact them during normal business hours using any mode (phone, email, text, voicemail) but the communication was to be related to the physical activity program only, such as pain during CALF and progress towards meeting goals."

RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

Does your paper address	CONSORT subitem 13a? *
-------------------------	------------------------

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. This is information is provided in the CONSORT flow diagram.

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. This is information is provided in the CONSORT flow diagram.

13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

	1	2	3	4	5	
subitem not at all important	۲	0	0	0	0	essential

Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. This is information is provided in the CONSORT flow diagram.

14a) Dates defining the periods of recruitment and follow-up

Does your paper address CONSORT subitem 14a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No. However, data were collected were collected 3-17-16 to 9/3/18.

14a-i) Indicate if critical "secular events" fell into the study period

Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"

	1	2	3	4	5	
subitem not at all important	0	0	0	0	٢	essential

Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The app was designed for iOS 8 or later, developed on Heroku cloud platform and beta tested through Apple TestFlight. Every three months the app's beta testing period expired and a new build of the app had to be uploaded by the developers to TestFlight for actively using the app. At these times the app also had to be updated and reinstalled, often leading to participant confusion and the inability to perform the leg exercises. "

14b) Why the trial ended or was stopped (early)

Does your paper address CONSORT subitem 14b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable. Target enrollment met.

15) A table showing baseline demographic and clinical characteristics for each

group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

Does your paper address CC	NSORT	subiter	n 15? *							
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study										
Yes.										
15-i) Report demographics as In ehealth trials it is particularly impo such as age, education, gender, socia participants, if known.	rtant to re	eport demo	ographics	associate	d with digit					
	1	2	3	4	5					
subitem not at all important	0	0	۲	0	0	essential				

Does your paper address subitem 15-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "8 individuals were incapable of operating a smartphone.

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

16-i) Report multiple "denominators" and provide definitions

Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential

Does your paper address subitem 16-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes as illustrated throughout the discussion section.

16-ii) Primary analysis should be intent-to-treat Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i). 1 2 3 4 5 subitem not at all important O O O O O essential

Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This trial was conducted under ITT principles.

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a? *


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. Confidence intervals are reported.

17a-i) Presentation of process outcomes such as metrics of use and intensity of

use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).



Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Data captured by the accelerometer BEAT was reported as the percentage of participants adherent to exercise duration defined as performing foot exercises at or above the recommended duration of \geq 15 seconds for each exercise (three exercises per session, three times per day) or not always adherent (moved foot < 15 seconds per exercise per session). Adherence to frequency was reported as the percentage of days the participants completed each CALF intensity level (3 levels performed 3 times per day [=9 levels], each performed over 2 weeks); 9 levels performed \geq 85% of the days throughout the study period was considered adherent to frequency. Participants were instructed to perform the exercises three times daily, increase the duration of time each subsequent day, and review additional information on the app as needed."

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes.

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CC	ONSORT	subiter	n 18? *							
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study										
Not applicable.										
18-i) Subgroup analysis of co A subgroup analysis of comparing or stressed that this is a self-selected s (see 16-iii).	nly users is	s not unco	mmon in e							
	1	2	3	4	5					
subitem not at all important	۲	0	0	0	0	essential				

Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable.

19) All important harms or unintended effects in each group

(for specific guidance see CONSORT for harms)

Does you	r paper	address	CONSORT	subitem	19? *
----------	---------	---------	---------	---------	-------

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No adverse events were reported that were viewed to be serious, related, or possibly related to this study protocol.

19-i) Include privacy breaches, technical problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].



Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No privacy breaches were reported during the conducted of this feasibility trial.

19-ii) Include qualitative feedback from participants or observations from

staff/researchers

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.



Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Participants indicated they liked FOOTFIT but due to many technical glitches, they believed they would rather do the exercises on their own and not rely on the system. Providers reported that participants told them the exercises helped relieve stiffness and lower leg pain, and "enjoyed being in the study." However, they also revealed to the providers that it was often difficult to operate the accelerometer and phone, corroborating the information reported to study staff. "

"The providers had no specific recommendations for refinements to reports of participant involvement other than they were too busy to review progress on a regular basis. In response to this challenge, study staff sent the reports each week to the provider, rather than the provider having to access the app site database to search and review data for each participant. The providers did not communicate feedback "back" from the reports to participants. Providers reported they inconsistently reviewed these reports if at all."

DISCUSSION

22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)


Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).



Does your paper address subitem 22-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "In our study, we investigated the feasibility of FOOTFIT that combined a foot worn accelerometer BEAT with a smartphone app, and evidence-based foot exercises CALF; in the FOOTFIT+ group, an additional patient-provider communication option (FOOTFIT+) was included. The intervention was developed to promote adherence to a six-week progressive exercise program suited to the needs and preferences of minimally ambulatory older adults with VLUs. Results showed participants had problems using the accelerometer and app but were mostly adherent to the exercise protocol. Minimal gains were made in exercise intensity and duration in both groups."



Does your paper address subitem 22-ii?


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Future mHealth interventions should consider adding tailored adherence-enhancing components such as added support (although the participants had access to the wound clinician) to positively influence behavior change, improve the functionality of the wearable device, and revise the app to make it more intuitive and bigger/easier to read on the phone and tablet. From our experience with 3 small trials, we advocate that providers such as wound specialists or primary care providers discuss patient preferences for engaging in the frequency and types of physical activity to enhance lower leg physical functioning."

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.



Does your paper address subitem 20-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, " Limitations of this study include a small sample size as this was a feasibility study. In addition, because the accelerometer and app were specifically designed for individuals with VLUs, the generalizability of results is limited. However, other minimally ambulatory populations with chronic conditions that have limited function may benefit from this type of physical activity approach. We recognize the intervention did not include a specific adherence-enhancing component other than daily alerts; there were no provisions for behavioral change support. Behavioral approaches should be incorporated into future designs to enhance motivation and user engagement. In addition, our evidence-based CALF program was specifically designed for a progressive, short initial exercise "boost" for minimally-ambulatory population, prior to them undertaking a more rigorous physical activity program. Thus our findings do not add to the fields of physical activity or exercise sciences in a way that advances our understanding of the influence of exercise on wound healing."

21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

21-i) Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations 1 2 3 4 5 subitem not at all important I I I 0 I 6

Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No. This was a targeted intervention for individuals with venous leg ulcers. However, this work could be extended among individuals with other lower extremity function conditions such as diabetic foot ulcers.

21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting. 1 2 3 4 5 subitem not at all important

Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No, this trial was conducted in a real-world clinical setting.

OTHER INFORMATION

23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "ClinicalTrials.gov: NTC02632695; https://clinicaltrials.gov/ct2/show/NCT02632695? term=physical+activity+leg+ulcer&rank=1"

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? *

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This materials is available upon request from the corresponding author.

25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "This project was supported by National Institutes of Health, National Institute of Nursing Research (TK – primary principal investigator), #R21NR015134, and in part, by the National Center for Advancing Translational Sciences of the National Institutes of Health under Grant Number UL1 TR001450."

X27) Conflicts of Interest (not a CONSORT item)

X27-i) State the relation of the In addition to the usual declaration of study team towards the system being identical with the developers/sponsor	interests evaluate	s (financial d, i.e., stat	or otherw e if the au	vise), also	state the r	elation of the
	1	2	3	4	5	
subitem not at all important	0	0	۲	0	0	essential
Does your paper address sub Copy and paste relevant sections from indicate direct quotes from your man information not in the ms, or briefly ex No conflict of interest declared.	n the mar uscript), c	nuscript (in or elaborat	e on this i	tem by pro	oviding add	ditional
About the CONSORT EHEAL	.TH che	ecklist				
As a result of using this chec O yes, major changes	klist, die	d you m	ake cha	nges in	your ma	nuscript? *
O yes, minor changes						
o no						

What were the most important changes you made as a result of using thi	S
checklist?	

Not applicable

How much time did you spend on going through the checklist INCLUDING
making changes in your manuscript *

3 hours

As a result of using this checklist, do you think your manuscript has improved? *
O yes
O no
• Other: The manuscript was already prepared in accordance with the eHealth Checklis
Would you like to become involved in the CONSORT EHEALTH group?
This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document
🔘 yes
o no
O Other:

Any other comments or questions on CONSORT EHEALTH

Not at this time.

STOP - Save this form as PDF before you click submit

To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit !

Click submit so we have your answers in our database!

Submit

Never submit passwords through Google Forms.

This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy

